Skip to main content
    P

    Prelude Therapeutics Inc (PRLD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.32
    -0.09 (-2.64%)

    Market Cap: $272.13M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Prelude Therapeutics Inc (PRLD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Prelude Therapeutics (PRLD) has a market cap of $272.13M and an enterprise value of $248.72M. It kept -247.12% of revenue as net income over the last 12 months. Its share count is up 35.41% from a year earlier.

    Total Valuation

    Enterprise value is 8.60% below the market cap, as cash exceeds debt.

    Market Cap$272.13M
    Enterprise Value$248.72M
    Latest price (Nov 17, 2026)$3.32

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 4.78% in the quarter ended Sep 30, 2026 and grew 16.58% a year over 2 years.

    Shares Outstanding103.09M
    Shares Change (YoY)+35.41%
    Shares Change (QoQ)+4.78%
    Share Count Growth (2Y CAGR)+16.58%

    Valuation Ratios

    Sales and book value multiples are 15.9x and 2.8x. Its year-end P/S ranged from 13.8x to 86.8x from 2023 to 2025.

    P/S Ratio15.9x
    Forward P/S7.0x
    P/B Ratio2.8x

    Valuation history and multiples

    Price Statistics

    The stock is up 118.42% over 52 weeks and trades 15.31% below its 50-day average.

    Beta (1Y)1.72
    52-Week Change+118.42%
    1-Month Change-2.06%
    3-Month Change-42.56%
    6-Month Change-22.25%
    5-Year Change-77.93%
    Total Return (1Y)+118.42%
    Total Return (3Y CAGR)-2.66%
    Total Return (5Y CAGR)-25.49%
    Return vs SPY (1Y)+86.06%
    Max Drawdown (1Y)-51.28%
    Max Drawdown (3Y)-90.42%
    Sharpe Ratio (1Y)0.64
    Correlation with SPY (1Y)0.22
    50-Day Average$3.92
    200-Day Average$4.11
    52-Week Range$1.29 to $6.83
    RSI (14 Days)37.5
    Average Volume (20 Days)294.27K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.20x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.20x
    Quick Ratio4.20x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -42.94% over the last 12 months, against a 5-year average of -78.24%.

    Return on Equity (ROE)-42.94%
    Return on Assets (ROA)-30.38%
    Return on Capital Employed (ROCE)-37.66%
    ROE (5Y Average)-78.24%
    ROA (5Y Average)-55.14%
    Asset Turnover0.16x

    Scores

    PRLD has an Altman Z-Score of -1.88, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score-1.88
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $21.57M over the last 12 months is up 105.44% from the 12 months before.

    Revenue$21.57M
    Revenue Growth (YoY)+105.44%
    Gross Profit$21.57M
    Operating Income-$61.24M
    Pretax Income-$53.31M
    Net Income-$53.31M
    EBITDA-$53.21M
    EBIT-$53.31M
    Reported EPS (TTM)-$0.59

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 70.74% of the $175.49M in total assets.

    Cash and Equivalents$23.41M
    Total Debt$0
    Net Cash$23.41M
    Net Cash Per Share$0.23
    Working Capital$108.50M
    Shareholder Equity$124.14M
    Book Value Per Share$1.20
    Total Assets$175.49M
    Total Liabilities$51.35M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$27.92M
    FCF Per Share-$0.43
    Depreciation and Amortization$2.91M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -283.92%.

    Gross Margin100.00%
    Operating Margin-283.92%
    Pretax Margin-247.12%
    Net Margin-247.12%
    EBITDA Margin-246.67%
    EBIT Margin-247.12%

    Growth

    Book Value Per Share Growth (2Y CAGR)-43.43%
    Tangible Book Per Share Growth (2Y CAGR)-43.43%

    Revenue and profit by year

    Dividends and Yields

    PRLD does not pay a dividend.

    Buyback Yield-5.91%
    Shareholder Yield-5.91%

    Peer Position

    Against 6 similar companies, PRLD has the 2nd highest P/S.

    P/S Ratio15.9x vs 5.7x median
    Revenue Growth (Trailing 4 Quarters, YoY)+105.44% vs -49.91% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 72.98% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+72.98%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About PRLD

    What is PRLD's market cap?

    Prelude Therapeutics has a market cap of $272.13M. Its enterprise value, which adds debt and subtracts cash, is $248.72M.

    How many shares of PRLD are outstanding?

    Prelude Therapeutics has 103.09M shares outstanding. The count is up 35.41% from a year earlier.

    Does PRLD pay a dividend?

    No. Prelude Therapeutics does not pay a dividend.

    How much debt does PRLD have?

    Prelude Therapeutics has $0 of total debt and $23.41M of cash and equivalents, a net cash position of $23.41M.